Danish Antag Therapeutics has chosen its main asset and is now preparing for pre-clinical and later clinical trials. At the same time, one more experienced biotech offier enters the board of directors.
Log in to read our articles
Welcome to MedWatch. A part of our content is exclusive and reserved for our users.